Pfizer Breakfast Talk: From idea to patient

13 feb '19
08:00 - 09:30
Gamla Gästmatsalen, Medicon Village, Lund
Pfizer in collaboration with Medicon Village and SmiLe Incubator

From a brilliant idea, lab tests and clinical trials to the first prescription. The care that precedes the cure.

When: Wednesday February 13, 08:30 – 09:30. Breakfast available from 08:00.

Where: Gamla Gästmatsalen, Medicon Village, Lund

Registration: Send an email, not later than February 6th, to


  • Pfizer Sweden: Marketing, Manufacturing and Science/Collaboration
    Christoph Varenhorst, Country Medical Director

  • Clinical Research
    Karolina Rask, Director Clinical Site Management, Scandinavia/Baltics

  • Ongoing collaborations
    Anders Mälarstig, Director Human Genetics

Christoph Varenhorst
Country Medical Director of Pfizer Sweden and associate professor of medicine. In his role at Pfizer, he provides the leadership to all in-country medical functions and is the country senior medical voice internally and externally.

Karolina Rask
Director Clinical Site Management, Scandinavia/Baltics, Molecular biologist with global experience from clinical research and work in both biotech and pharma. Responsible for Pfizer’s clinical studies run in the Nordic and Baltic region.

Anders Mälarstig
Anders Mälarstig is a Director of Human Genetics in the Target Sciences and Technologies unit at Pfizer R&D. The unit focuses on early target discovery and validation with strong human confidence in rationale. Anders is embedded at the Karolinska Institute to lead external collaborations at KI, in the Nordics and UK